2 Phototherapies Used in Medicine

Photobiomodulation and Photodynamic Therapy in Treating COVID Related Issues

Regarding COVID, both of these modalities should theoretically be useful, perhaps even critically important if they can be combined.

1. We need to kill the virus as soon and as quickly as possible post infection. For this Photodynamic Therapy with a Photosensitizing agent that can target the virus, followed by its “matched” frequency (wavelength) of light that is absorbed by the Photosensitizing agent would destroy the virus.

• The patient receives an IV of the needed photosensitizing agent. An incubation period is employed to ensure that the PS agent has sufficiently penetrated all the tissues where the virus is lurking.
• At the end of the incubation period the “matched” light is administered to the patient. In cases of systemic infection, intravascular administration of the appropriate frequency of laser light will ensure the most effective exposure of the treated virus to the “matched” laser light.
• Subsequently, the energized Photosensitizing agent will generate ROS that are deadly to the virus.

Note: Ideally, in the case of an early onset of the infection, a properly constructed protocol that takes advantage of these properties will clear a patient of an entire viral load quickly, and before systemic damage is created.

Note: On the other hand, if the infection has been lingering for a sufficiently long period of time wherein systemic inflammation has caused ischemic organ damage, symptoms subsequent to the organ damage may persist long after the pathogen has been eliminated. See below.

• Once the virus has been killed, the patient may still experience many Long-Haul symptoms that persist for many weeks. This is due to the ubiquitous tissue and organ damage caused by the spike protein’s ability to invade the cells despite the absence of the actual virus. Once inside, the spike protein’s disruption of the Electron Transport Chain disables the cell from being able to generate sufficient energy to effectively repair itself and return its host organ to a healthy state.

Furthermore, because of ischemic tissue damage caused by systemic inflammation and the abnormal toxic clotting (also caused by the spike protein), restoring healthy cellular activity via the effect of PBM, that stimulates proliferation might enhance and accelerate a COVID patient’s recovery.

2. Ideally, a magical combination of the “right” Photodynamic protocol that successfully kills the COVID virus, followed by the ”right” Photobiomodulation protocol to heal and rebuild damaged tissue, would be the most effective way to heal COVID patients, especially those who postponed early treatment allowing the virus to proliferate unchecked causing extensive damage.

Another Example is Cystic Acne

ALA (5-aminolaevulinic acid) is spread on the effected skin and allowed to “incubate” for 45 min to 3 hours depending on the severity of the lesions. Skin cancers require longer incubation periods.

During the incubation, the ALA saturates the cysts, who because of their hyperactive cystic activity are also saturated with naturally produced porphyrins.

Thereafter, when the correctly “matched” blue light is shined on the treated skin, through a variety of reactions between the ALA the Porphyrins and the blue light, powerfully toxic ROS such as a singlet oxygen is created that will kill the cystic cells.

Photodynamic Therapy and Drug Resistant Pathogenic Microbes

As the list of drug resistant microbes continues to grow, their virulence also grows, as does the list of obsolete antibiotics.

In contrast, Photodynamic Therapy does not engage pathogens at the genetic level where resistance can be developed. Consequently, there is an increasing focus on developing new Photodynamic Protocols, including laser devices and novel photosensitizing compounds to which resistance cannot be developed.

A perfect example is the use of Methylene Blue as the photosensitizing agent of Photodynamic Therapy.

1. Methylene Blue inactivates Zika virus and Sindbis virus.
2. Methylene Blue + light inactivates West Nile virus.
3. Methylene Blue + light reduces Ebola virus infectivity.
4. Methylene Blue + light reduces Middle East respiratory syndrome virus infectivity.
5. Methylene Blue + light reduces HIV-1 “to nondetectable levels”.
6. Methylene Blue + light reduces Bovine Diarrhea virus “to non-detectable levels”.
7. Methylene Blue + light reduces Pseudorabies virus “to non-detectable levels”.
8. Methylene Blue + light reduces Hepatitis A virus.
9. Methylene Blue + light reduces Porcine Parvovirus.
10. Methylene Blue + light inactivates Enterovirus.
11. Methylene Blue + light inactivates Flavivirus.
12. Methylene Blue + light inactivates Herpes virus.
13. Methylene Blue + light reduces Dengue virus.

Photodynamic Therapy, Photobiomodulation and Viruses

Among the many pathogens that can be targeted by PDT, viruses are perhaps the most vulnerable, as they depend on entering a host cell for survival and replication and can be inactivated by damaging the capsid or envelope molecules (lipids, carbohydrates, proteins) or internal molecules (nucleic acids).

Thus, many viruses can be treated via PDT, including papillomavirus (HPV), hepatitis A virus (HAV), and herpes simplex virus (HSV).

In general, it is believed that light energy excitation of endogenous microbial intracellular light receptors (chromophores), such as porphyrins and flavins is the mechanism of action that eliminates pathogenic microbes. Once excited, these receptors undergo energy transfer processes that lead to the generation of cytotoxic ROS which react with intracellular components resulting in photodamage and cell death by oxidative stress.

Additionally, the laboratory disinfection of biological fluids (plasma and blood products) by photo antimicrobials has been performed for decades and is a well-regarded technological application of these compounds.

For instance, extracorporeal photoinactivation of coronaviruses and other clinically relevant pathogens using methylene blue (MB)-mediated PDT has been reported.

Photobiomodulation has been used in the treatment of acute lung injury, pulmonary inflammation, and acute respiratory distress syndrome (ARDS), due to its ability to substantially reduce systemic inflammation while preserving lung function.

Though the mechanism is of yet unknown, Photobiomodulation is also effective in treating disseminated intravascular coagulation.

In Conclusion

According to current research, Photobiomodulation and Photodynamic Therapy employing lasers and LEDs are here to stay. The existing information appears to support the hypothesis that Phototherapy does not rely solely on coherence and high energy production to produce favorable physiological effects, but also on selective wavelength application, optimal absorption, and photo-activation.

The significant combination of Photodynamic and Photobiomodulation therapies listed above are evidence of light energy’s untapped promise in the realm of regenerative medicine. Further development of Phototherapy will provide widespread clinical application and acceptance of Photomedicine and have a direct, beneficial impact on mankind by radically changing the ways we manage cancer, acute and chronic wounds, inflammation, and antimicrobial resistance.